BACKGROUND AND PURPOSE: A retrospective study evaluating the role of hypofractionated stereotactic proton beam therapy for acoustic neuromas. MATERIALS AND METHODS: The data of 51 patients treated with hypofractionation (3 fractions) and followed up for a minimum of 2 years, were analyzed. Mean dose prescribed to ICRU reference point (isocenter) was 26 cobalt gray equivalent (CGyE) in 3 fractions. Mean minimum tumor dose was 21.4 CGyE/3. Cranial nerve functions were evaluated clinically. Serial MR Scans were used to evaluate local control. RESULTS: With a mean clinical and radiological follow-up of 72 and 60 months respectively, the 5-year results showed a 98% local control, with a hearing preservation of 42%, a facial nerve preservation of 90.5% and a trigeminal nerve preservation of 93%. CONCLUSION: For those patients harboring large acoustic neuromas that are inoperable, hypofractionated stereotactic proton beam offers long-term control with minimal side-effects.
BACKGROUND AND PURPOSE: A retrospective study evaluating the role of hypofractionated stereotactic proton beam therapy for acoustic neuromas. MATERIALS AND METHODS: The data of 51 patients treated with hypofractionation (3 fractions) and followed up for a minimum of 2 years, were analyzed. Mean dose prescribed to ICRU reference point (isocenter) was 26 cobalt gray equivalent (CGyE) in 3 fractions. Mean minimum tumor dose was 21.4 CGyE/3. Cranial nerve functions were evaluated clinically. Serial MR Scans were used to evaluate local control. RESULTS: With a mean clinical and radiological follow-up of 72 and 60 months respectively, the 5-year results showed a 98% local control, with a hearing preservation of 42%, a facial nerve preservation of 90.5% and a trigeminal nerve preservation of 93%. CONCLUSION: For those patients harboring large acoustic neuromas that are inoperable, hypofractionated stereotactic proton beam offers long-term control with minimal side-effects.
Authors: Anurag Saraf; Luke R G Pike; Kevin H Franck; Nora K Horick; Beow Y Yeap; Barbara C Fullerton; Irene S Wang; Mohamed E Abazeed; Michael J McKenna; William A Mehan; Scott R Plotkin; Jay S Loeffler; Helen A Shih Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Simeng Zhu; Ronny Rotondo; William M Mendenhall; Roi Dagan; Debbie Lewis; Soon Huh; Glenn Knox; Daryoush Tavaniepour; Sukhwinder Sandhu; Michael S Rutenberg Journal: Int J Part Ther Date: 2018-07-26
Authors: Mira A Patel; Ariel E Marciscano; Chen Hu; Ignacio Jusué-Torres; Rupen Garg; Arif Rashid; Howard W Francis; Michael Lim; Kristin J Redmond; Daniele Rigamonti; Lawrence R Kleinberg Journal: Front Oncol Date: 2017-09-04 Impact factor: 6.244
Authors: Hussain AlHussain; Ali Balbaid; Robert Malyapa; Majid AlOthman; Yasser A Bahadur; Mutahir A Tunio; Mushabbab Al Asiri Journal: Saudi Med J Date: 2019-09 Impact factor: 1.484
Authors: Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-01